EchoGo® Heart Failure vs Zio AT ECG Monitoring System
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 60/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
Tool A, EchoGo® Heart Failure, is designed for the AI-powered detection of HFpEF by analyzing routine echocardiograms, providing rapid insights to support clinical decisions. In contrast, Tool B, the Zio AT ECG Monitoring System, is a wearable mobile cardiac telemetry service that uses AI for continuous, long-term ECG monitoring to detect arrhythmias. While both are cardiology AI tools, they address different cardiac conditions and utilize distinct diagnostic modalities, making them adjacent rather than direct competitors.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
EchoGou00ae Heart Failure is an AI platform designed to analyze routine echocardiograms specifically for the detection of Heart Failure with preserved Ejection Fraction (HFpEF). The Zio AT ECG Monitoring System, conversely, is a wearable mobile cardiac telemetry service focused on continuous, AI-powered ECG monitoring for long-term arrhythmia detection.
EchoGou00ae Heart Failure analyzes existing routine echocardiogram video clips to provide insights within 20 minutes. In contrast, the Zio AT system uses a wearable patch for continuous ECG recording for up to 14 days to detect cardiac events.
EchoGou00ae Heart Failure offers seamless integration with existing workflows and IT stacks, delivering automated structured reports via DICOM to PACS. The Zio AT system utilizes a ZioSuiteu00ae clinician portal and mobile app for patient management and report interpretation, with real-time data transmission from the wearable patch.
EchoGou00ae Heart Failure is reimbursable via CPT code 0932T for outpatient analysis, with a national Medicare average of $316 per analysis, and is covered by Medicare and select commercial insurers. Pricing details for the Zio AT ECG Monitoring System are not publicly disclosed, typically involving service fees for monitoring and analysis.
EchoGou00ae Heart Failure is clinically validated with 90% sensitivity and 86% specificity for HFpEF detection. The Zio AT system uses an FDA-cleared deep-learned AI algorithm (ZEUS System) for arrhythmia detection, but specific sensitivity and specificity metrics are not provided in the available information.
EchoGou00ae Heart Failure is designed for Cardiology, Emergency Medicine, and Internal Medicine specialties. The Zio AT ECG Monitoring System is primarily focused on Cardiology.
More Comparisons
Backers
Who funded each tool's parent company.